ProCE Banner Activity

The Role of Brain Cholesterol Inhibition in the Treatment of Epilepsy

Clinical Thought

As the treatment landscape of epilepsy—including rare developmental and epileptic encephalopathies—evolves, novel approaches are necessary to ensure patients’ quality of life are not severely impacted by adverse events. The cholesterol 24-hydroxylase inhibitor soticlestat shows promise in reducing frequency and severity of seizures, while being highly tolerable compared to placebo.

Released: September 15, 2023

Share

Faculty

Jonathan J. Halford

Jonathan J. Halford, MD

Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, South Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. 

Takeda Pharmaceuticals U.S.A., Inc.